Cargando…

Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism

Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Jiahui, Berthet, Amandine, Citron, Y. Rose, Tsiolaki, Paraskevi L., Stanley, Robert, Gestwicki, Jason E., Agard, David A., McConlogue, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102405/
https://www.ncbi.nlm.nih.gov/pubmed/33798554
http://dx.doi.org/10.1016/j.jbc.2021.100613
_version_ 1783689096358526976
author Tao, Jiahui
Berthet, Amandine
Citron, Y. Rose
Tsiolaki, Paraskevi L.
Stanley, Robert
Gestwicki, Jason E.
Agard, David A.
McConlogue, Lisa
author_facet Tao, Jiahui
Berthet, Amandine
Citron, Y. Rose
Tsiolaki, Paraskevi L.
Stanley, Robert
Gestwicki, Jason E.
Agard, David A.
McConlogue, Lisa
author_sort Tao, Jiahui
collection PubMed
description Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet there is minimal mechanistic understanding of this important protective pathway. It is generally assumed that Hsp70 binds to ASyn using its canonical and promiscuous substrate-binding cleft to limit aggregation. Here we report that this activity is due to a novel and unexpected mode of Hsp70 action, involving neither ATP nor the typical substrate-binding cleft. We use novel ASyn oligomerization assays to show that Hsp70 directly blocks ASyn oligomerization, an early event in ASyn misfolding. Using truncations, mutations, and inhibitors, we confirm that Hsp70 interacts with ASyn via an as yet unidentified, noncanonical interaction site in the C-terminal domain. Finally, we report a biological role for a similar mode of action in H4 neuroglioma cells. Together, these findings suggest that new chemical approaches will be required to target the Hsp70-ASyn interaction in synucleinopathies. Such approaches are likely to be more specific than targeting Hsp70’s canonical action. Additionally, these results raise the question of whether other misfolded proteins might also engage Hsp70 via the same noncanonical mechanism.
format Online
Article
Text
id pubmed-8102405
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-81024052021-05-14 Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism Tao, Jiahui Berthet, Amandine Citron, Y. Rose Tsiolaki, Paraskevi L. Stanley, Robert Gestwicki, Jason E. Agard, David A. McConlogue, Lisa J Biol Chem Research Article Overexpression and aggregation of α-synuclein (ASyn) are linked to the onset and pathology of Parkinson’s disease and related synucleinopathies. Elevated levels of the stress-induced chaperone Hsp70 protect against ASyn misfolding and ASyn-driven neurodegeneration in cell and animal models, yet there is minimal mechanistic understanding of this important protective pathway. It is generally assumed that Hsp70 binds to ASyn using its canonical and promiscuous substrate-binding cleft to limit aggregation. Here we report that this activity is due to a novel and unexpected mode of Hsp70 action, involving neither ATP nor the typical substrate-binding cleft. We use novel ASyn oligomerization assays to show that Hsp70 directly blocks ASyn oligomerization, an early event in ASyn misfolding. Using truncations, mutations, and inhibitors, we confirm that Hsp70 interacts with ASyn via an as yet unidentified, noncanonical interaction site in the C-terminal domain. Finally, we report a biological role for a similar mode of action in H4 neuroglioma cells. Together, these findings suggest that new chemical approaches will be required to target the Hsp70-ASyn interaction in synucleinopathies. Such approaches are likely to be more specific than targeting Hsp70’s canonical action. Additionally, these results raise the question of whether other misfolded proteins might also engage Hsp70 via the same noncanonical mechanism. American Society for Biochemistry and Molecular Biology 2021-03-30 /pmc/articles/PMC8102405/ /pubmed/33798554 http://dx.doi.org/10.1016/j.jbc.2021.100613 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Tao, Jiahui
Berthet, Amandine
Citron, Y. Rose
Tsiolaki, Paraskevi L.
Stanley, Robert
Gestwicki, Jason E.
Agard, David A.
McConlogue, Lisa
Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title_full Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title_fullStr Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title_full_unstemmed Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title_short Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
title_sort hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102405/
https://www.ncbi.nlm.nih.gov/pubmed/33798554
http://dx.doi.org/10.1016/j.jbc.2021.100613
work_keys_str_mv AT taojiahui hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT berthetamandine hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT citronyrose hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT tsiolakiparaskevil hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT stanleyrobert hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT gestwickijasone hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT agarddavida hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism
AT mcconloguelisa hsp70chaperoneblocksasynucleinoligomerformationviaanovelengagementmechanism